Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.

  Audit Compensation Governance and Nominating
Stephen C. McCluski
Stephen C. McCluski
Former Senior Vice President and Chief Financial Officer, Bausch & Lomb

Stephen C. McCluski has been a director of ImmunoGen since 2007, and has served as the Chairman of our Board of Directors since 2009. Mr. McCluski served as Senior Vice President and Chief Financial Officer of Bausch & Lomb Incorporated from 1995 to his retirement in 2007. Mr. McCluski is also a director of Monro Muffler Brake, Inc. and the James P. Wilmot Cancer Center of the University of Rochester.

Chair of the Audit Committee    
Mark Goldberg M.D.
Mark Goldberg M.D.
Senior Vice President of Product Development and Internal Advisor, Synageva BioPharma Corp.

Mark Goldberg, MD, has been a director of ImmunoGen since 2011. Dr. Goldberg served in various capacities of increasing responsibility at Synageva BioPharma Corp., a biopharmaceutical company, from 2011 to 2014, including as Executive Vice President, Medical and Regulatory Strategy of Product Development. From October 2014 through the aquisition of Synageva by Alexion Pharmaceuticals, Inc. in June 2015, Dr. Goldberg, while no longer an officer, remained employed by Synageva contributing to medical and regulatory strategy. Prior to joining Synageva he served in various management capacities of increasing responsibility at Genzyme Corporation from 1996 to 2011, most recently as Senior Vice President, Clinical Research and Global Therapeutic Head, Oncology, Genetic Health, and as Chairman of Genzyme’s Early Product Review Board. Prior to joining Genzyme he was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, where he still holds appointments. Dr. Goldberg is an Associate Professor of Medicine at Harvard Medical School. Dr. Goldberg holds a Doctor of Medicine degree from Harvard Medical School. Dr. Goldberg is also a director of aTyr Pharma, Inc., Blueprint Medicines Corporation, GlycoMimetics, Inc. and Idera Pharmaceuticals, Inc.

    Member of the Governance and Nominating Committee
Dean Mitchell
Dean Mitchell
President and CEO, Lux Biosciences, Inc

Dean J. Mitchell has been a director of ImmunoGen since 2012. Mr. Mitchell has served as Executive Chairman of the Board of Covis Pharma Holdings S.a.r.l. since 2013. Prior to that he served as President and Chief Executive Officer of Lux Biosciences, Inc. from 2010 to August 2013. Prior to that he served as President and Chief Executive Officer of Alpharma, Inc. from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008. Prior to that he served as President and Chief Executive Officer of Guilford Pharmaceuticals, Inc. from 2004 until its acquisition by MGI PHARMA, INC. in 2005. Prior to that he served in various senior executive capacities in the worldwide medicines group of Bristol-Myers Squibb Company from 2001 to 2004. Prior to that he spent 14 years at GlaxoSmithKline plc in assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. Mr. Mitchell is also a director of Inrexon, Inc. and Theravance BioPharma, Inc.

  Member of the Compensation Committee  
Kristine Peterson
Kristine Peterson
CEO, Valeritas, Inc.

Kristine Peterson has served as director of ImmunoGen since 2012. Ms. Peterson served as Chief Executive Officer of Valeritas, Inc. from 2009-2016. Prior to that she served as Company Group Chair of Johnson & Johnson’s biotech groups from 2006 to 2009, and as Executive Vice President for J&J’s global strategic marketing organization from 2004 to 2006. Prior to that she served as Senior Vice President, Commercial Operations for Biovail Corporation and President of Biovail Pharmaceuticals from 2003 to 2004. Prior to that she spent 20 years at Bristol-Myers Squibb Company in assignments of increasing responsibility spanning marketing, sales and general management, including running a cardiovascular/metabolic business unit and a generics division. Ms. Peterson is also a director of Amarin Corporation plc and Paratek Pharmaceuticals, Inc.

Member of the Audit Committee Member of the Compensation Committee  
Howard Pien
Howard Pien
Former Chairman of the Board and Chief Executive Officer of Medarex, Inc.

Howard H. Pien has served as a director of ImmunoGen since 2009. Mr. Pien has most recently served as Chairman of the Board and Chief Executive Officer of Medarex, Inc. from 2007 to its acquisition by Bristol-Myers Squibb Company in 2009. Prior to that he was a private consultant from 2006 to 2007. Prior to that he served as President and Chief Executive Officer of Chiron Corporation from 2003 to its acquisition by Novartis AG in 2006. Prior to that he served in various executive capacities at GlaxoSmithKline plc (GSK) and its predecessor companies, including as President of GSK’s International Pharmaceuticals business from 2000 to 2003, and as President of Pharmaceutical Operations of SmithKline Beecham plc (a predecessor of GSK). Mr. Pien also worked for six years at Abbott Laboratories and for five years at Merck & Co., Inc. in positions in sales, market research, licensing and product management. Mr. Pien is also currently an advisor to the life sciences practice of Warburg Pincus, a private equity firm, as well as a director of Indivior PLC (as non-executive chairman), Juno Therapeutics, Inc. (as non-executive chairman), Sage Therapeutics, Inc. and Vanda Pharmaceuticals, Inc.

  Chair of the Compensation Committee  
Joseph J. Villafranca Ph.D.
Joseph J. Villafranca Ph.D.
Senior Vice President, Life Sciences, Business Development, Tunnell Consulting

Joseph J. Villafranca, PhD, has served as director of ImmunoGen since 2004. Dr. Villafranca has served as President of BioPharmaceutical Consultants LLC since 2012. Prior to that he served as Senior Vice President, SOU Head, Life Sciences, of Tunnell Consulting from 2009 to his retirement from Tunnell Consulting in 2012. Prior to that he served as Senior Vice President – Operations and Principal & Practice Director, Life Sciences, of Tunnell Consulting from 2006 to 2009. Prior to that he served as President of Biopharmaceutical Consultants LLC from 2005 to 2006. Prior to that he served as Executive Vice President, Pharmaceutical Development and Operations at Neose Technologies, Inc. from 2002 to 2005. Prior to that he served in various executive positions at Bristol-Myers Squibb Company over a period of 11 years. Dr. Villafranca holds a PhD in Biochemistry/Chemistry from Purdue University and completed his postdoctoral work at the Institute for Cancer Research in Philadelphia, Pennsylvania.

    Chair of the Governance and Nominating Committee
Richard J. Wallace
Richard J. Wallace
Former Senior Vice President of Research and Development at GlaxoSmithKline

Richard J. Wallace has been a director of ImmunoGen since 2007. Mr. Wallace served as a Senior Vice President for Research and Development at GlaxoSmithKline plc (GSK) from 2004 to his retirement in 2008. Prior to that he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace’s experience prior to joining GSK included eight years with Bristol-Myers Squibb Company and seven years at Johnson & Johnson (in assignments spanning marketing, sales, manufacturing and general management). Mr. Wallace is also a director of GNC Holdings, Inc.

Member of the Audit Committee   Member of the Governance and Nominating Committee
= Chair of the Board = Chair = Member = Financial Expert

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue